Dose finding study of irinotecan for UGT1A1 homozygnous group

ABSTRACT: Interventions: Administraion of irinotecan is twice for 4 weeks . Adjusted dosage is determined from 100or125 mg/sqm in the heterozygous group . Primary outcome(s): adverse events Study Design: Single arm Non-randomized

DISEASE(S): Gastric Cancer,colorectal Cancer,lung Cancer,ovarian Cancer,cervical Cancer And Brest Cancer

PROVIDER: 2617831 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR